Hank Klakurka has over 40 years of experience in the global pharmaceuticals industry and has extensive experience in both branded and generic pharmaceuticals. He is the former CEO of Merck Generics Group and played a key role in its sale to US-based Mylan for US$6.7B in 2007. He grew the Merck Generics business from approximately €900m to €1.8B since joining the company in 2001 as head of its Americas Region. He was promoted to CEO of the group in 2003. Prior to joining Merck, Mr. Klakurka held various leadership positions with major pharma companies including Astra AB, Schering-Plough, Johnson & Johnson and Apotex. In addition to advising Private Equity funds on Healthcare investments, he currently is President of Hank Klakurka and Associates Inc., advising Pharma firms on strategic matters in the USA and Canada. In the SEA region, he currently serves on the Board of Directors for SOHO Global Health.

He holds a B.S. from the University of Toronto and has completed Merck’s business programs at Insead, Kellogg, HKUST and IMD.